Corpus ID: 26001124

CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease.

@article{Mandel2010CERE110AA,
  title={CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease.},
  author={R. Mandel},
  journal={Current opinion in molecular therapeutics},
  year={2010},
  volume={12 2},
  pages={
          240-7
        }
}
  • R. Mandel
  • Published 2010
  • Medicine
  • Current opinion in molecular therapeutics
To date, only five drugs have been approved for the treatment of Alzheimer's disease (AD); however, these agents impact the symptoms rather than the progression of the disease. It is well established that nerve growth factor (NGF) enhances the function and survival of basal forebrain cholinergic neurons that are vulnerable in AD. However, NGF does not cross the blood-brain barrier, and intraventricular NGF injections in animals and humans were associated with significant side effects. Adeno… Expand
Current viral-mediated gene transfer research for treatment of Alzheimer’s disease
  • A. O. Sasmita
  • Medicine
  • Biotechnology & genetic engineering reviews
  • 2019
Gene transfer to the CNS is efficacious in immune-primed mice harboring physiologically relevant titers of anti-AAV antibodies.
Adeno-Associated Virus Vectors and Neurological Gene Therapy
Biosafety of recombinant adeno-associated virus vectors.
Viral vector-based models of Parkinson's disease.
Acat1 knockdown gene therapy decreases amyloid-β in a mouse model of Alzheimer's disease.
...
1
2
3
4
5
...